Atai Life Sciences N.V.
ATAI
$1.47
$0.053.52%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -1.91% | -0.90% | 39.48% | 2.97% | 35.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.91% | -0.90% | 39.48% | 2.97% | 35.34% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -1.91% | -0.90% | 39.48% | 2.97% | 35.34% |
| SG&A Expenses | -26.40% | -6.92% | -10.06% | -6.11% | -11.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.29% | -17.54% | -21.32% | -18.80% | -15.26% |
| Operating Income | 18.33% | 17.58% | 21.44% | 18.84% | 15.34% |
| Income Before Tax | -233.45% | -104.57% | 56.60% | 73.81% | 70.02% |
| Income Tax Expenses | 24.00% | -136.19% | -130.35% | -128.38% | -122.94% |
| Earnings from Continuing Operations | -241.83% | -82.35% | 59.78% | 76.06% | 72.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -78.75% | -64.18% | -54.72% | -43.96% | -27.05% |
| Net Income | -271.09% | -92.11% | 59.97% | 77.26% | 73.60% |
| EBIT | 18.33% | 17.58% | 21.44% | 18.84% | 15.34% |
| EBITDA | 18.50% | 17.68% | 21.55% | 18.98% | 15.46% |
| EPS Basic | -263.87% | -89.51% | 61.44% | 77.76% | 73.82% |
| Normalized Basic EPS | -14.44% | -10.47% | -2.74% | 16.30% | 17.05% |
| EPS Diluted | -220.43% | -74.13% | 58.03% | 74.31% | 70.50% |
| Normalized Diluted EPS | -17.52% | -13.27% | -0.40% | 18.58% | 19.22% |
| Average Basic Shares Outstanding | 2.30% | 2.02% | 1.12% | 0.68% | 0.55% |
| Average Diluted Shares Outstanding | -1.14% | -1.41% | 4.59% | 4.16% | 4.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |